We are live on ! Find out more
JY

Jeff Yass Susquehanna International Group

AUM $1.28T
1-Year Est. Return 58.89%
 

Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.

This Fund
S&P 500
This Quarter Est. Return
-4.48%
1 Year Est. Return
+58.89%
3 Year Est. Return
+161.44%
5 Year Est. Return
+153.95%
10 Year Est. Return
+561.69%
AUM
$387B
AUM Growth
-$17.5B
Cap. Flow
-$6.97B
Cap. Flow %
-1.8%
Top 10 Hldgs %
31.87%
Holding
14,936
New
2,167
Increased
5,455
Reduced
5,274
Closed
1,852

Sector Composition

Rank Sector Weight
1 Technology 1.87%
2 Consumer Discretionary 1.66%
3 Communication Services 1.09%
4 Financials 1.07%
5 Energy 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CSCI
14201
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
-1,890
Closed -$36.2K
AIFF
14202
PUT
Firefly Neuroscience
AIFF
$16.9M
-417
Closed -$17K
QNTM
14203
PUT
Quantum Biopharma Class B Subordinate Voting Shares
QNTM
$144
-235
Closed -$12K
NIXX
14204
Nixxy Inc
NIXX
$19.6M
-1,074
Closed -$16K
DWTX
14205
Dogwood Therapeutics
DWTX
$84.6M
-915
Closed -$129K
AIVC
14206
Amplify Bloomberg AI Equal Weight ETF
AIVC
$127M
-74,268
Closed -$2.33M
AIFU
14207
AIFU Inc
AIFU
$110M
-202
Closed -$417K
GRCE
14208
Grace Therapeutics
GRCE
$46.3M
-4,327
Closed -$22K
SUNE
14209
SUNation Energy
SUNE
$9.4M
0
-$95K
MTVA
14210
MetaVia Inc
MTVA
$9.62M
-41
Closed -$51K
PVLA
14211
Palvella Therapeutics
PVLA
$2.05B
-421
Closed -$54.3K
PVLA
14212
PUT
Palvella Therapeutics
PVLA
$2.05B
-130
Closed -$19K
JBTM
14213
CALL
JBT Marel
JBTM
$6.06B
-2,000
Closed -$221K
AEVAW
14214
DELISTED
Aeva Technologies Warrants
AEVAW
-13,995
Closed -$7K
WHWK
14215
Whitehawk Therapeutics
WHWK
$270M
-30,306
Closed -$398K
HEAL
14216
Global X Funds Global X HealthTech ETF
HEAL
$33M
-51,149
Closed -$1.77M
ENZ
14217
DELISTED
Enzo Biochem, Inc.
ENZ
-21,943
Closed -$53K
PEV
14218
DELISTED
Phoenix Motor Inc. Common Stock
PEV
-102,625
Closed -$486K
ATSG
14219
CALL
DELISTED
Air Transport Services Group
ATSG
-19,900
Closed -$572K
CLRCR
14220
DELISTED
ClimateRock Right
CLRCR
-31,631
Closed -$3K
XDAP
14221
DELISTED
Innovator U.S. Equity Accelerated ETF - April
XDAP
-29,320
Closed -$714K
SBT
14222
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
-27,885
Closed -$159K
ALTR
14223
CALL
DELISTED
Altair Engineering Inc
ALTR
-3,800
Closed -$200K
EDR
14224
DELISTED
Endeavor Group Holdings, Inc.
EDR
-194,927
Closed -$4.41M
SYRS
14225
PUT
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
-1,000
Closed -$10K

Similar funds

Jeff Yass's Q3 2022 Portfolio in Review

As of Q3 2022, Jeff Yass held 14,936 positions worth $387B, down 4.3% from $404B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Jeff Yass's Q3 2022 filing shows 2,167 new, 5,455 increased, 5,274 reduced and 1,852 closed positions. Its largest new stake was Vanguard Short-Term Corporate Bond ETF: 714,572 shares worth $53.1M. The largest sale was Tesla, an estimated $799M.

By sector, the portfolio is most concentrated in Technology at 1.9% of assets, up from 1.8% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • Jeff Yass's largest Q3 2022 buy was Vanguard Short-Term Corporate Bond ETF: 714,572 shares worth $53.1M.
  • Jeff Yass added most to Amazon in Q3 2022, an estimated $1.21B increase.
  • Jeff Yass's biggest Q3 2022 reduction was Tesla, cutting an estimated $799M.
  • Jeff Yass fully exited Pershing Square Tontine Holdings, Ltd. in Q3 2022, selling an estimated $151M.
  • Jeff Yass's ten largest holdings make up 32% of its $387B portfolio in Q3 2022.
  • Jeff Yass opened 2,167 new positions and closed 1,852 in Q3 2022.
  • Jeff Yass's portfolio value fell 4.3% quarter-over-quarter to $387B.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.